Porcine Vaccines Market - Snapshot
The global porcine vaccines market is expanding due to growing prevalence of swine diseases across the globe. The global porcine vaccines market was valued at US$ 1,784.0 Mn in 2016 and is projected to expand at a compounded annual growth rate (CAGR) of over 7.0% from 2017 to 2025, to reach value of US$ 3,208.8 Mn by 2025. The global market is witnessing growth at a relatively high rate, owing to rise in investments by governments in the field of animal health care, high incidence of swine fever, increase in R&D expenses incurred for eradicating porcine health issues, and surge in the demand for porcine meat and gelatin.
Porcine vaccine is an administrative as well as clinical drug that helps in improving health of swine and protects them from deadly viruses, bacteria, and pathogens. Diseases such as diarrhea, swine influenza, porcine reproductive and respiratory syndrome, and porcine circovirus associated disease (PCVAD) have been greatly reduced from spreading in an endemic manner. A few diseases such as foot & mouth disease and cholera high fever have been eliminated in swine in North America and Europe through vaccination. The success of animal vaccination remains as an ideal interval for booster vaccination.
A porcine vaccine aids the swine or hogs suffering from epidemic porcine diseases. It also improves overall efficiency in protecting pigs from deadly viruses and increases the production level of high-quality meat for consumption. High prevalence and incidence rates of porcine epidemic diarrhea (PED), swine flu, and porcine reproductive and respiratory syndrome (PRRS) in swine production farms worldwide have resulted in increase in early vaccination of piglets and adult pigs. There has been increase in the number of awareness programs about porcine diseases and rise in the number of joint venture programs by key players in different regions for research and development of swine vaccines. These factors are collectively projected to drive the demand for porcine vaccines across the world in the near future. Also, technological advancements such as combined vaccine production and DNA vaccines enable agriculture farmers to produce disease-free pigs. This factor is estimated to fuel the porcine vaccines market in the near future.
The global porcine vaccines market has been broadly segmented based on technology, disease indication, end-user, and region. In terms of technology, the global market has been categorized into inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. The inactivated vaccines segment accounted for a key share (in terms of revenue) of the global market in 2016. The live attenuated vaccines segment is estimated to expand at a significant growth rate during the forecast period and is estimated to gain a significant market share by 2025. DNA vaccines also offer several advantages over live attenuated vaccines and inactivated vaccines and thus, DNA vaccines are increasingly gaining popularity among veterinary hospitals and hog production farms.
In terms of disease indication, the global porcine vaccines market has been divided into diarrhea, swine influenza, arthritis, Bordetella rhinitis, porcine reproductive and respiratory syndrome (PRRS), porcine circovirus associated disease (PCVAD), and others (CHRS, leptospirosis, etc.). Diarrhea and swine influenza segments dominated the global market in 2016 and are likely to continue their dominance from 2017 to 2025, with a marginal increase in their market shares by 2025. Increasing production of pigs in farms for meat, gelatin, and other products; changes in climate including global warming; overfeeding of protein diet; and increasing occurrence of genetically modified strains of influenza viruses have led to significant shares held by diarrhea and swine influenza segments in the global market. In terms of end-user, the global market has been divided into veterinary hospitals and hog production farms. The hog production farms segment is estimated to gain a significant market share by 2025, due to increasing demand for production of pigs for meat and other products.
Geographically, the global porcine vaccines market has been segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2016 and is projected to lose market share by 2025. The market in North America is primarily driven by rapid increase in pig cultivation and rise in infection of pigs caused by viruses such as PEDV, PCV, and PRRSV in the U.S. Moreover, rise in contract farming and independent farming for pig production has been observed in the U.S., which is projected to fuel the hog production farms segment of the market in the U.S. during the forecast period. Asia Pacific is projected to be a rapidly expanding market for porcine vaccines during the forecast period. China dominates the porcine vaccines market in Asia Pacific. The market in Rest of Asia Pacific (including Vietnam, the Philippines, etc.) is estimated to expand at a significant CAGR during the forecast period.
Companies such as Boehringer Ingelheim GmbH, Ceva Santé Animale, Elanco (Eli Lilly and Company), Merck & Co., Inc., and Zoetis, Inc. were major players in the global porcine vaccines market in 2016. Zoetis, Inc. dominated the market with its diversified product portfolio, extensive geographical presence, and acquisition strategies. In 2015, the company invested over US$ 1.0 Bn in two largest acquisitions. One of them was the acquisition of PHARMAQ, which strengthened Zoetis’ core livestock business division. Other players operating in the global market include Bimeda Animal Health, Vetoquinol, and Bayer AG. Companies are adopting the strategy of acquisitions and collaborations to enhance and strengthen their geographical presence.
Porcine Vaccines Market - Overview
This report on the porcine vaccines market analyzes the current and future scenario of the global market. Increase in the prevalence of diseases among swine, technological advancements of RNA strand methodology, and cultivation of pigs to raise standards of living are likely to drive the global porcine vaccines market during the forecast period. Increase in the number of trading facilities for live hogs/pigs, rise in the demand for pork meat, and innovations through clinical research activities are some of the factors expected to drive the global porcine vaccines market during the forecast period.
This report on the global porcine vaccines market comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the market with respect to segments based on disease indication, technology, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises Porter’s five forces analysis to help understand the competition landscape of the market. This section also provides market attractiveness analysis, in terms of country, and market share analysis, by key players, thereby presenting a thorough analysis of the overall competition scenario in the global porcine vaccines market.
Based on technology, the porcine vaccines market has been segmented into inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. These market segments have been extensively analyzed based on increase in the demand for treatment of diseases such as PED, PRRS, and PCVAD. Surging demand for disease-free pork meat and increasing awareness for treating cultivated pigs are driving the technology segments of the market. Different types of end-users utilize porcine vaccines to treat swine diseases. Among end-users, the hog production farms segment holds a major share, followed by the veterinary hospitals segment. The market size (in terms of US$ Mn) and forecast for each segment have been provided for the period from 2015 to 2025. The report also provides the compounded annual growth rate (CAGR %) for each segment for the period from 2017 to 2025, considering 2016 as the base year.
Based on disease indication, the market has been segmented into diarrhoea, swine influenza, porcine reproductive and respiratory syndrome (PRRS), porcine circovirus associated disease (PCVAD), and others. Diarrhoea is the most widespread disease among pigs across the world. Porcine epidemic diarrhea virus (PEDV) hit the U.S. in 2013 and spread to Canada in 2014, which infected piglets. It had 80%–100% mortality rate. The above-mentioned segments have been analyzed based on available approved products, their cost-effectiveness, and preference by veterinarians for treating swine with various disease indications. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the period from 2017 to 2025, considering 2016 as the base year.
Geographically, the global porcine vaccines market has been categorized into five major regions and key countries/sub-regions in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, Russia, France, Spain, Italy, Russia, and Rest of Europe), Asia Pacific (Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2015 to 2025, along with their respective CAGRs for the period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competition scenario in the market in these regions.
The report also profiles major players in the global porcine vaccines market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report are Bayer AG., Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Santé Animale, Elanco (Eli Lilly and Company), Merck & Co., Inc., Vetoquinol, and Zoetis Inc.
The global porcine vaccines market has been segmented as below:
Global Porcine Vaccines Market, by Disease Indication, 2015–2025
- Swine Influenza
- Bordetella Rhinitis
- Porcine Reproductive and Respiratory Syndrome (PRRS)
- Porcine Circovirus Associated Disease (PCVAD)
- Others (CHRS, Leptospirosis, etc.)
Global Porcine Vaccines Market, by Technology, 2015–2025
- Inactivated Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Conjugate Vaccines
- DNA Vaccines
Global Porcine Vaccines Market, by End-user, 2015–2025
- Veterinary Hospitals
- Hog Production Farms
Global Porcine Vaccines Market, by Geography, 2015–2025
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa